New methodology for the synthesis of several 4H-pyrido[1,2-a]pyrimidin-4-ones has been developed from commercially available 2-aminopyridines and β-oxo esters catalysed by Montmorillonite under solvent-free conditions in good yields. This methodology was expanded for the synthesis of 4H-pyrimido[1,2-a]pyrimidin-4-one derivatives from 2-aminopyrimidine and different β-keto esters. The new methodology for the synthesis of N-alkylated 6-methyl 2-pyridones and N-alkylated 2-methyl 4-pyridones, from commercially available starting materials was developed. For the synthesis of N-alkylated 6-methyl 2-pyridones, 2-methoxy-6-methyl pyridine and a number of different alkylating reagents have been employed as starting materials. For the synthesis of N-alkylated 2-methyl 4-pyridones, 4-chloro 2-methyl pyridine was used successfully to make the desired pyridone in 3 steps. Selective mono-metallation at the 6-methyl substituent of N-alkylated 6-methyl 2-pyridones and N-alkylated 2-methyl 4-pyridones with n-BuLi/KHMDS at -78 °C proceeded smoothly, and the reactivity of the lithiated intermediates towards a wide range of electrophile (diketones, aldehydes, alkylating reagents) was studied. A straightforward synthesis of desirable 4H-quinolizin-4-one scaffolds by condensation of N-benzyl 6-methyl 2-pyridones with dicarbonyl compounds, and the formation of the desired quinolizinone after the condensation step was achieved. An unexpected quinolizinone bearing a fused β-lactam ring was isolated and its structure confirmed by single crystal X-ray diffraction analysis.

Techn. Universiẗat, Diss., 2004--Darmstadt.

An extensive overview of the current state of the research in the field of the development of acyclic nucleoside phosphonates (ANPs) was elaborated, which quotes from 196 publications in abstracted journals. A new microwave-assisted methodology for the preparation of dialkyl haloalkylphosphonates was developed. Through strict control of the reaction temperatures in microwave reactor, it was possible to lower the amount of the reactants all the way to the ideal ratio of 1:1. With the use of a continuous-flow microwave reactor, it was possible to prepare the key building blocks for the subsequent syntheses of ANPs in large quantities (100 g), which significantly accelerates research in this area. The new method was patented and published. While studying various ANP prodrugs, a new highly effective methodology for the preparation of the diamides of ANPs was developed. The method starts directly from ANP diesters, which react with trimethylsilylbromide to form the corresponding bis(trimethylsilyl)esters of ANPs, which are well soluble in organic solvents and react smoothly during the subsequent introduction of aminoacid esters. Moreover, the reaction with trimethylsilylbromide protects the reactive groups present in the rest of the molecule and thus prevents undesired side reactions. Furthermore, using...

A microwave reactor was used to synthesize a series of novel 3,6-disubstituted or 3-substituted pyrazolo[1,5-a]pyrimidines in a total of 1 hour reaction time over 3 steps. The products were obtained in good to excellent yields (34-92%, ave = 52%) using a straightforward synthesis starting with the reaction of dimethylformamide-dimethylacetal with commercially available aryl acetonitriles (120C, 20 min). This was followed by treatment with H2NNH2 • HBr (120C, 20 min), and then reacted with either 1,1,3,3-tetramethoxypropane or a 2-aryl-substituted malondialdehydes (120C, 20 min). The resulting product was either collected on a sintered glass funnel or purified via column chromatography. The compounds were screened for anti-cancer activity against A2780 Ovarian and/or MCF7 breast cancer cell lines in vitro. The most active compounds were the 3-(4-(trifluoromethyl)phenyl)-6-[4-(2-(piperidin-1-yl)ethoxy]phenyl analogue and the 3-(2-fluorophenyl)-6-[4-(2-(4-methylpiperzin-1-yl)ethoxy]phenyl analogue, exhibiting EC50 values of 0.84 and 0.52 M respectively, which is 2-3 times more potent than Dorsomorphin. Several of the derivatives also showed promising activities against several viruses of emerging concern, including HBV, MERS Coronavirus, Zika, and Ebola. Use of a microwave reactor to synthesize N’-aryl/(alkyl) substituted N-[(4-hydroxy-6-phenyl)pyrimidin-2-yl]guanidines or N-[(4-hydroxy-6-trifluoromethyl)pyrimidin-2-yl]guanidines from the corresponding cyanamides with alkyl/aryl amines was achieved in good to excellent yields (39-96%, ave = 62%) in 10 minutes at 120C using only 1 equivalent of amine. Work-up was exceptionally simple, and involved collecting precipitated solids on a sintered glass funnel and washing with cold 2-propanol. Products were obtained in analytically pure form and required approximately 1 hour to prepare, start to finish. Compounds in this series showed early promise as potential inhibitors of A2780 Ovarian cancer, in vitro.

A library of 25 novel 3,6-disubstituted and 3-substituted pyrazolo[1,5-a]pyrimidines were synthesized using a microwave chemical reactor in 3 steps with a total reaction time of 1 hour. The products were obtained in good to excellent yields (20-93%, ave. = 62%). The synthesis began with the reaction of aryl acetonitriles with dimethylformamide-dimethylacetal (120C, 20 min), followed by treatment of the resulting 2-arylacrylonitrile with H2NNH2 • HBr (120C, 20 min). The intermediate 4-arylpyrazol-5-amine obtained was finally reacted with either 2-aryl-substituted malondialdehydes or 1,1,3,3-tetramethoxypropane (120C, 20 min) to give the final products. The products were either collected directly on a Buchner funnel or purified via flash chromatography. The compounds were screened for anti-cancer activity against the A2780 Ovarian cancer cell line in vitro at 10 µM. The most active compound was the 2-(pyrazolo[1,5-a]pyrimidin-3-yl)benzothiazole, herein referred to as RD-I-53, which had an EC50 value of 0.9 µM nearly mirroring the experimental control, Dorsomorphin, which had an EC50 of 1.1 µM. RD-I-53 was screened against a panel of 453 kinases by DiscoverX in a KinomeScan™, a competitive binding inhibition assay wherein RD-I-53 selectively inhibited VPS34 kinase and JAK1-JH2 pseudokinase (Kd VPS34 = 0.4µM, Kd JAK-1 JH2 = 0.5µM). NCI-60 data revealed selective anticancer activity of RD-I-53 against the MCF-7 and MDA-MB-468 breast cancer cell lines. Virtual docking studies of RD-I-53 against the VPS34 active site and its derivatives resulted in the creation of a virtual library of new compounds with potentially improved anticancer activity. A highly convergent route was developed to facilitate the ease of access to derivatives of RD-I-53. In the process, new methodologies for the synthesis of 2-aminobenzothiazoles and the thiocyanation of non-C4-substituted anilines and heterocycles were investigated and reported. A library of derivatives of RD-I-53 has been synthesized to be screened for potentially improved kinase inhibitory and anti-cancer activity.